Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gemfibrozil treatment: a comparison with clofibrate.

A N Howard, P Ghosh

    Proceedings of the Royal Society of Medicine
    |January 1, 1976
    PubMed
    Summary

    Gemfibrozil effectively lowers triglycerides in specific hyperlipoproteinaemia types. At 800 mg/day, its lipid-lowering effect is comparable to 1.5 g/day of clofibrate.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Phospholipid oxidation and carotenoid supplementation in Alzheimer's disease patients.

    Free radical biology & medicine·2017
    Same author

    Lutein and atherosclerosis: Belfast versus Toulouse revisited.

    Medical hypotheses·2016
    Same author

    Sustained supplementation and monitored response with differing carotenoid formulations in early age-related macular degeneration.

    Eye (London, England)·2015
    Same author

    Founding of the International Journal of Obesity: a journey in medical journalism.

    International journal of obesity (2005)·2014
    Same author

    Creatine supplementation, sleep deprivation, cortisol, melatonin and behavior.

    Physiology & behavior·2006
    Same author

    Acute ingestion of red wine by men activates platelets but does not influence endothelial markers: no effect of white wine.

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis·2002

    Area of Science:

    • Pharmacology
    • Clinical Medicine
    • Lipid Metabolism

    Background:

    • Hyperlipoproteinaemia is a group of genetic disorders characterized by elevated levels of lipoproteins.
    • Types IIb, IV, and V hyperlipoproteinaemia are associated with increased cardiovascular risk.
    • Hypotriglyceridaemic agents are crucial for managing these conditions.

    Purpose of the Study:

    • To evaluate the efficacy of gemfibrozil as a hypotriglyceridaemic agent.
    • To compare the effectiveness of gemfibrozil with clofibrate in treating hyperlipoproteinaemia.

    Main Methods:

    • The study assessed gemfibrozil's impact on triglyceride levels.
    • Gemfibrozil was administered at a daily dose of 800 mg.
    • Its efficacy was compared to a daily dose of 1.5 g of clofibrate.

    Main Results:

    • Gemfibrozil demonstrated significant hypotriglyceridaemic activity.
    • The agent was effective in patients with types IV, IIb, and V hyperlipoproteinaemia.
    • An 800 mg/day dose of gemfibrozil showed efficacy comparable to 1.5 g/day of clofibrate.

    Conclusions:

    • Gemfibrozil is an effective treatment for types IV, IIb, and V hyperlipoproteinaemia.
    • Gemfibrozil offers a comparable therapeutic effect to clofibrate at a lower dosage.
    • Gemfibrozil represents a viable option for hypotriglyceridaemic therapy.

    Related Experiment Videos